medigraphic.com
ISSN 0188-2198 (Print)

2007, Number 1

<< Back Next >>

Rev Mex Cardiol 2007; 18 (1)

Effectiveness and safety of amphepramone in a slow release as part of the integral management of obesity

Morín ZR, Lonngi VS, Ponce LML, Alcaraz OR, Barragán DILA

Language: Spanish
References: 24
Page: 9-16
PDF size: 122.02 Kb.


ABSTRACT

Background: Amphepramone (diethylpropion) is one of the first synthetic anorexigenics developed, however recent studies following current experimental designs for these drugs are required. In addition, slow release formulations has shown advantages, mainly from the safety point of view, therefore slow release formulations of anorexigenics has been developed. Objective: Evaluate the effectiveness, but mainly the safety of amphepramone in a slow release formulation as part of the integral management of obesity. Patients and procedure: Sixty obese (BMI ≥ 30) adult patients were treated during six months plus one withdrawal month. Participants were randomly assigned to one of two groups: placebo (P) or slow release amphepramone 75 mg/day (LLANF). Hypocaloric diet and a 30 minutes walk five days per week were also indicated. Medical history was done at day 0 and at 30 days intervals. Laboratory tests were performed on days 0, 90, 180 y 210. A difference of p ‹ 0.05 was considered as statistically significant. Results: Both groups lose weigh and reduce their BMI. However, these changes were earlier and more pronounced in the LLANF group. Reduction was observed mainly in body fat and was associated with waist circumference reduction. With the intention to treat analysis, the weigh lost at 180 days was 5.0 ± 4.8 kg (5.3%) and a waist reduction of 6.3 cm in the P group and 9.2 ± 4.8 kg (10.3%) and 10.4 cm of waist with LLANF (p ‹ 0.05 vs basal in both groups). Non-statistical but clinically significative reduction of LDL–c and triglycerides were observed. Adverse events were mild, occurred mainly in the first three months of therapy and do not required withdrawal. Also, no deleterious laboratory changes were detected. Conclusion: These results confirm the effectiveness and safety of the amphepramone slow release formulation amid in the integral management of obese patients. Because their profile and background, amphepramone should be study in obese comorbid patients, mainly those with cardiovascular disease.


REFERENCES

  1. Rivera-Domarco J, Barquera S, González-Cossio T, Olaiz G, Sepúlveda J. Nutrition transition in México and other Latin American countries. Nutr Rev 2004; 62: S149-S157.

  2. González J, Gómez M, Chavarría S. Epidemiología de la obesidad. En: González Barranco J. Obesidad. 1ª Ed. Mc Graw-Hill Interamericana. México 2004.

  3. Bray G. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119(7 pt 2): 707-713.

  4. Finkelstein E, Fiebelkorn I, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obesity Research 2004; 12: 18-24.

  5. Prescription medications for the treatment of obesity. NIDDK. NIH No. 97-4191. Febrero 2001.

  6. Atkinson RL, Hubbard VS. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr 1994; 60: 153-6.

  7. Yanovski S, Yanovski J. Obesity. N Engl J Med 2002; 346: 591-602.

  8. Yu H, Rothman R, Dersch C, Partilla J, Rice K. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem 2000; 8: 2689-2692.

  9. Silverstone T. Appetite suppressants: a review. Drugs 1992; 43: 820-36.

  10. Hoffman B, Lefkowitz R. Catecolaminas y drogas simpaticomiméticas. En: Goodman y Gilman. Las bases farmacológicas de la terapéutica. 8ª ed. Editorial Médica Panamericana México 1991.

  11. Morín R, Lonngi G. Simpaticomiméticos catecolaminérgicos con acción anorexigénica. En: Farmacoterapia de la obesidad. 1ª ed. México 1995 ISBN 968-7987-11-1.

  12. Braguinsky J, Viñuales M, Franganillo L. Tratamiento farmacológico de la obesidad. En: Obesidad patogenia, clínica y tratamiento. 2ª ed. El Ateneo Buenos Aires 1996.

  13. Weiser M. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-473.

  14. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-57.

  15. Morín R, Lonngi G, Alcaraz R, Rosas D. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses. Med Int Mex 2001; 17: 260-71.

  16. Morín ZR, Ponce LM, Lonngi VS, Alcaraz OR Lonngi VG. Dos formulaciones de fenproporex de liberación lenta como tratamiento de la obesidad. Rev Mex Cardiol 2005; 16: 146-154.

  17. Tapia CR, Velázquez MO, Lara EA, Sánchez CC, Fanghanel SG, Sánchez L y cols. Manual. Prevención, promoción de la salud y tratamiento de la obesidad. Mídete la cintura. Programa de Salud del Adulto y el Anciano. Secretaría de Salud.

  18. Bolding OT. Diethylpropion hydrochloride: an effective appetite suppressant. Curr Ther Res 1974; 16: 40-8.

  19. Li Z, Maglione M, Tu W, Mojica W, Arterbum D, Shugarman L et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.

  20. Vallé Jones JC, Brodie NH, O’Hara H, O’Hara J, McGhie RL. A comparative study of phentermine and diethylpropion in the treatment of obeses patients in general practice. Pharmatherapeutica 1983; 3: 300-304.

  21. Castañeda G, Cail Ike G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin Pharmacokinet 1994; 26: 135-143.

  22. Guidance for the Clinical Evaluation of Weigh-Control Drugs. Division of Metabolic and Endocrine Drug Products Food and Drug Administration 9-24-96.

  23. Fanghanel G, Guerra A, Franco V, Iza R, Sánchez-Reyes L, Alfaro E, Espinoza R. Obesidad y dislipidemia. En 1er Consenso Mexicano para el Diagnóstico y Tratamiento de las Dislipidemias. Ed Intersistemas, S.A. de C.V. México 2005.

  24. Kinnell H. European withdrawal of appetite suppressants. Obes Rev 2003; 4: 79-81.




2020     |     www.medigraphic.com